Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001980:Bronchi / Q000187:drug effects*; D002493:Central Nervous System Diseases / Q000139:chemically induced*; D003638:Deafness / Q000139:chemically induced; D003875:Drug Eruptions; D004342:Drug Hypersensitivity; D005128:Eye Diseases / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006327:Heart Block / Q000139:chemically induced; D006331:Heart Diseases / Q000139:chemically induced*; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced*; D009369:Neoplasms / Q000139:chemically induced; D009469:Neuromuscular Junction / Q000187:drug effects*; D010538:Peritonitis / Q000139:chemically induced; D011217:Practolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011928:Raynaud Disease / Q000139:chemically induced*; D013375:Substance Withdrawal Syndrome
D000319:Adrenergic beta-Antagonists; D011433:Propranolol; D011217:Practolol